Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that CEO and Board Chair, Roger M. Perlmutter, M.D., Ph.D., and CFO, Alfred “Freddie” Bowie, Ph.D., will provide a business update at Morgan Stanley’s 22nd Annual Global Healthcare Conference in New York City on September 4, 2024 at 8:30am ET. Their presentation will cover recent advancements in the company’s pipeline and clinical development programs, as well as updates related to its Eikon Systems business.

Investors and interested parties can access an audio recording of the event at www.EikonTx.com/news.

About Eikon Therapeutics

Eikon Therapeutics seeks to advance breakthrough therapeutics through the purposeful integration of engineering and science. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to people suffering from grievous illness. Eikon operates from its facilities in California, New Jersey, and New York and can be found online at www.EikonTx.com or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240826577405/en/